Jounce Therapeutics, Inc.
JNCE
|
$1.88
-2.59%
-1.85%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-1.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 98,954,680
http://www.jouncetx.com
Sec Filling | Patents | 130 employees
(US) Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
cancer immunotherapy t-cell ceiling
add to watch list Paper trade email alert is off
Press-releases
Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte
Published: 2023-07-31 (Crawled : 09:00) - prnewswire.com
TYRA | $16.02 -2.2% -2.25% 62K
|
Health Technology
|
| O: -0.42%
H: 8.05%
C: 3.71%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.34%
H: 1.07%
C: -1.81%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
URGN | $14.24 -2.0% -2.04% 97K
|
Health Technology
|
| O: -1.59%
H: 0.94%
C: -2.65%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.56%
H: 0.0%
C: 0.0%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -0.73%
H: 4.99%
C: -0.96%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.03%
H: 1.4%
C: 1.03%
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 6.38%
H: 0.33%
C: -6.67%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: -1.71%
H: 3.48%
C: -5.43%
companies expected growth market
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
Published: 2023-07-10 (Crawled : 12:00) - globenewswire.com
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: 0.49%
H: 0.97%
C: -0.97%
VCEL | $46.09 -0.71% -0.72% 200K
|
Health Technology
|
| O: 0.06%
H: 3.86%
C: 3.3%
therapeutics
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
Published: 2023-06-28 (Crawled : 11:00) - globenewswire.com
KA 4 | $0.6202 -7.41% -8.0% 170K
|
Manufacturing
|
| O: 3.0%
H: 0.01%
C: -11.49%
ABOS | $3.17 0.32% 0.32% 150K
|
Professional, Scientific, and T...
|
| O: -0.42%
H: 4.0%
C: 2.32%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
biotech
Jounce Therapeutics Announces Closing of Tender Offer
Published: 2023-05-04 (Crawled : 00:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
| Email alert
Add to watchlist
therapeutics
Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm
Published: 2023-03-23 (Crawled : 23:00) - prnewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -1.97%
H: 0.0%
C: 0.0%
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
Published: 2023-03-16 (Crawled : 21:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
| Email alert
Add to watchlist
jtx-8064 review cancer trial therapeutics results ovarian cancer pimivalimab pd-1 inhibitor not effective drug
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Published: 2023-03-15 (Crawled : 03:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 44.55%
H: 12.33%
C: 2.05%
unsolicited therapeutics proposal
INVESTIGATION ALERT: Halper Sadeh LLC Investigates INDT, FOCS, JNCE, PTRS
Published: 2023-03-07 (Crawled : 17:00) - prnewswire.com
LNKB | $6.7 2.29% 2.24% 21K
|
Finance and Insurance
|
| O: -1.14%
H: 1.15%
C: 0.51%
INDT 4 | $66.99 0.02% 0.0% 0
|
Real Estate and Rental and Leas...
|
| O: 0.0%
H: 0.09%
C: -0.06%
PTRS | $7.15 0.0% 160K
|
Finance
|
| O: 0.11%
H: 0.01%
C: -0.33%
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -1.85%
H: 2.83%
C: -0.94%
FOCS | $52.99 -0.02% -0.04% 6.8M
|
Finance
|
| O: -0.02%
H: 0.1%
C: 0.06%
Moore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law Firm
Published: 2023-03-01 (Crawled : 21:00) - prnewswire.com
ROCC 4 | $37.47 0.61% 5.7M
|
|
| O: 1.1%
H: 2.01%
C: 1.25%
RC | $8.82 -0.56% 0.0% 1.1M
|
Finance
|
| O: -0.9%
H: 0.73%
C: -0.37%
BRMK | $4.82 1.45% 10M
|
Finance
|
| O: -2.91%
H: 1.1%
C: -1.0%
FOCS | $52.99 -0.02% -0.04% 6.8M
|
Finance
|
| O: 0.0%
H: 0.08%
C: 0.06%
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Focus Financial Partners Inc. - FOCS
Published: 2023-02-28 (Crawled : 04:00) - prnewswire.com
BRMK | $4.82 1.45% 10M
|
Finance
|
| O: 1.01%
H: 3.9%
C: 2.0%
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: -2.54%
H: 4.35%
C: -2.61%
FOCS | $52.99 -0.02% -0.04% 6.8M
|
Finance
|
| O: -0.04%
H: 0.31%
C: 0.25%
financial
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10